Pediatric SAKI Subphenotypes Predict Outcomes, Inform Treatment Responses

Unpacking Pediatric Sepsis-Associated Acute Kidney Injury

Sepsis-associated acute kidney injury (SAKI) remains a frequent and severe complication in pediatric critical care, linked to higher mortality and longer intensive care unit stays [1, 2]. While sepsis itself affects millions and carries a high disease burden [3, 4], the management of SAKI is complicated by significant biological heterogeneity among patients, suggesting that standard, one-size-fits-all protocols may be insufficient [5, 6]. The absence of specific, disease-modifying treatments for SAKI has intensified the search for precision medicine strategies that can parse this complexity, identify distinct patient subgroups, and ultimately tailor interventions to individual biologies [7]. A recent study provides a potential framework for achieving this goal by validating two distinct subphenotypes of pediatric SAKI.

Identifying Distinct Pediatric SAKI Subgroups

The clinical heterogeneity of sepsis-associated acute kidney injury (SAKI) has long been a barrier to developing effective, targeted therapies. To address this, researchers conducted a secondary analysis of a large, ongoing prospective study to externally validate two previously identified pediatric SAKI subphenotypes, pSAKI-1 and pSAKI-2, which are defined using readily available clinical data. The investigation drew from a cohort of patients aged 1 week to 18 years who presented with early SAKI (on day 1 or 2) at one of ten pediatric intensive care units in the United States between January 2002 and February 2025. Of the 871 patients analyzed, the subphenotyping algorithm classified 665 (76%) as pSAKI-1 and the remaining 206 (24%) as pSAKI-2, establishing a foundation for comparing their clinical characteristics and outcomes.

Subphenotype pSAKI-2: A Profile of Increased Severity and Worse Outcomes

A clear and clinically significant distinction emerged between the two subphenotypes early in the disease course. On days 1 and 2, the pSAKI-2 cohort consistently demonstrated a greater severity of illness. This was not a subtle difference; these patients presented with a higher acute kidney injury stage, required more vasoactive support, and had lower platelet counts, higher lactate values, and higher International Normalized Ratios compared to their pSAKI-1 counterparts. This initial profile of greater physiological derangement translated directly into poorer clinical trajectories. After adjusting for confounders, patients in the pSAKI-2 group had independently higher odds of developing severe acute kidney injury by day 7 (adjusted odds ratio [aOR] 3.2; 95% CI, 2.1-4.7; p < 0.001) and independently higher odds of death (aOR 2.7; 95% CI, 1.6-4.4; p < 0.001). Their recovery was also slower, marked by fewer PICU-free and vasoactive-free days (p < 0.001), confirming that these subphenotypes have substantial prognostic relevance.

Molecular Signatures Distinguish SAKI Subphenotypes

To understand the biological basis for these divergent outcomes, the researchers examined the molecular profiles of the two groups. The findings revealed that the pSAKI-2 subphenotype is not just a clinical descriptor but is associated with a distinct biomarker signature. Specifically, the pSAKI-2 profile was characterized by greater inflammation, providing a molecular correlate for the observed clinical severity. This signature also pointed to significant endothelial dysfunction, a state of vascular damage that can impair organ perfusion and exacerbate kidney injury. Furthermore, the pSAKI-2 group exhibited hyperreninemia, or elevated renin levels. As a key activator of the renin-angiotensin-aldosterone system, excess renin can drive vasoconstriction and fluid retention, creating a feedback loop that worsens renal injury. Together, these molecular findings paint a picture of a distinct pathophysiology for pSAKI-2, helping to explain why these patients fare so much worse.

Differential Treatment Responses to Corticosteroids and Vasopressin

A critical question was whether these subphenotypes respond differently to common sepsis therapies, a concept known as heterogeneity of treatment effect. Using propensity score matching, a statistical method that creates comparable patient groups to minimize confounding, the researchers found a striking interaction with corticosteroids. In the pSAKI-1 subphenotype, corticosteroid administration was associated with significantly worse outcomes, including more day 7 severe acute kidney injury (28% vs. 19%, p = 0.023), 2 fewer PICU-free days (p = 0.04), and a nearly threefold increase in mortality (10% vs. 3.7%, p = 0.008). In stark contrast, these detrimental effects were not observed in pSAKI-2 patients. For vasopressin, the propensity score matched analysis did not identify a differential effect. However, a different statistical approach, inverse probability treatment weighting, which also adjusts for treatment selection bias, revealed a significant interaction between subphenotype, vasopressin use, and the number of vasoactive-free days (p = 0.003). This suggests that the benefit of vasopressin on weaning vasoactive support may indeed differ between the two groups, though the effect is more complex.

Implications for Precision Medicine in Pediatric SAKI

This study successfully provides external validation for two pediatric SAKI subphenotypes that are identifiable using readily available clinical data. The findings confirm that the pSAKI-2 subphenotype is associated with a more severe clinical presentation, a distinct molecular signature of inflammation and endothelial injury, and substantially worse outcomes. Perhaps most importantly for the practicing clinician, the research demonstrates that these subphenotypes exhibit differential responses to treatment. The evidence of potential harm from corticosteroids specifically in the pSAKI-1 group is a powerful example of this heterogeneity. The authors conclude that these subphenotypes represent a viable mechanism for bedside enrichment, a strategy for selecting specific patients for clinical trials or targeted therapies. By moving beyond a uniform approach, this subphenotyping framework offers a tangible step toward precision medicine, potentially allowing clinicians to one day tailor SAKI management to a patient's specific biological profile, avoiding harm and optimizing care.

References

1. Lintz VC, Vieira R, Carioca F, et al. Fluid accumulation in critically ill children: a systematic review and meta-analysis. EClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.102714

2. Messmer AS, Zingg C, Müller M, Gerber JL, Schefold JC, Pfortmueller CA. Fluid Overload and Mortality in Adult Critical Care Patients—A Systematic Review and Meta-Analysis of Observational Studies*. Critical Care Medicine. 2020. doi:10.1097/ccm.0000000000004617

3. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020. doi:10.1016/s0140-6736(19)32989-7

4. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Medicine. 2021. doi:10.1097/ccm.0000000000005337

5. Rhodes A, Evans L, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine. 2017. doi:10.1097/ccm.0000000000002255

6. Vijendra B, Bertol AB, Almeida MMGD, Freitas PHAGD, Simão ÁMS, Faria BLD. Balanced crystalloid versus saline for resuscitation in pediatric septic shock: a systematic review and meta-analysis. BMC Pediatrics. 2025. doi:10.1186/s12887-025-05442-w

7. Goldstein BA, Návar AM, Pencina M, Ioannidis JPA. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. Journal of the American Medical Informatics Association. 2016. doi:10.1093/jamia/ocw042